Literature DB >> 16019448

Do alpha deletions influence hydroxyurea response in thalassemia intermedia?

I Panigrahi1, A Dixit, S Arora, M Kabra, M Mahapatra, V P Choudhry, R Saxena.   

Abstract

Thalassemia intermedia patients show variable phenotypes. Hydroxyurea (HU) may benefit some of the thalassemia intermedia cases (1), however, the parameters influencing the response to HU have not been reported. In this study, the molecular parameters, alpha-globin and beta-globin genotype and the Xmn I polymorphism, were correlated with the HU response. Twenty patients with thalassemia intermedia were given HU (10-20 mg/kg) and responses were evaluated over a one year period. Twelve patients (60%) showed a good response to therapy with a significant increase in Hb and HbF levels and with elimination of the transfusion requirement in four patients. Four out of the twelve (33%) patients were positive for -alpha(3.7) deletions whereas none of the 8 non-responders were positive for alpha deletions. One each of the responders and non-responders were positive for alpha alpha alpha(anti-3.7) triplication. Three (25%) responsive and one non-responsive patients were homozygous for the IVS1-1 (G-->T) mutation. Three of the responsive patients with alpha deletions were also homozygous positive for Xmn I polymorphism. Thus, in addition to acting in synergy with the XmnI polymorphism, alpha deletions may be an independent factor predicting good response to HU in thalassemia intermedia, although this needs to be confirmation in larger studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16019448     DOI: 10.1080/10245330400020439

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  6 in total

Review 1.  β-thalassemia intermedia: a clinical perspective.

Authors:  Khaled M Musallam; Ali T Taher; Eliezer A Rachmilewitz
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

2.  Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.

Authors:  Mehran Karimi; Sezaneh Haghpanah; Ali Farhadi; Majid Yavarian
Journal:  Int J Hematol       Date:  2011-12-20       Impact factor: 2.490

3.  Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity.

Authors:  Farzin Pourfarzad; Marieke von Lindern; Azita Azarkeivan; Jun Hou; Sima Kheradmand Kia; Fatemehsadat Esteghamat; Wilfred van Ijcken; Sjaak Philipsen; Hossein Najmabadi; Frank Grosveld
Journal:  Haematologica       Date:  2012-10-25       Impact factor: 9.941

Review 4.  Past, present & future scenario of thalassaemic care & control in India.

Authors:  Ishwar C Verma; Renu Saxena; Sudha Kohli
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375

Review 5.  β-Thalassemia Intermedia: A Bird's-Eye View.

Authors:  Anthony Haddad; Paul Tyan; Amr Radwan; Naji Mallat; Ali Taher
Journal:  Turk J Haematol       Date:  2014-03-05       Impact factor: 1.831

6.  Hydroxyurea could be a good clinically relevant iron chelator.

Authors:  Khushnooma Italia; Roshan Colah; Kanjaksha Ghosh
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.